We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urinary Markers Predict Bone Problems after Hip Replacement

By LabMedica International staff writers
Posted on 20 Jun 2018
Osteolysis is an active resorption of bone matrix by osteoclasts and can be interpreted as the reverse of ossification. More...
Although osteoclasts are active during the natural formation of healthy bone the term "osteolysis" specifically refers to a pathological process.

Peri‐implant osteolysis is commonly diagnosed after substantial bone loss has occurred, making revision surgery more challenging. A method has been developed was to identify urinary biomarkers that differentiate total hip replacement patients who eventually develop osteolysis from patients who do not.

Scientists at Rush University Medical Center (Chicago, IL, USA) used a repository of 24‐hour urine samples collected prior to surgery and annually thereafter in 26 patients, 16 who developed osteolysis, and 10 who did not. They examined the markers at radiographic diagnosis, annually for six years preceding diagnosis, at the first post‐operative sampling point, and pre‐operatively. Patients in the osteolysis and non‐osteolysis groups were matched according to time post‐surgery and did not differ in the male:female ratio or age at surgery.

The team measured seven candidate biomarkers, including free deoxypyridinoline (DPD), cross‐linked N‐telopeptides (NTX), interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), osteoprotegerin (OPG), α‐crosslaps (α‐CTX), and β‐crosslaps (β‐CTX). The scientists found that as an individual biomarker, DPD demonstrated the highest ability to predict osteolysis, with an area under the curve (AUC) in Receiver Operating Characteristic (ROC) analyses of 0.844 at six years prior to diagnosis. A panel of α‐CTX and IL‐6 was able to identify at‐risk patients with an AUC of 0.941 or greater at all post‐operative time points and an AUC of 1.000 pre‐operatively.

The authors concluded that their results demonstrate the potential of using non‐invasive biomarkers to identify patients at risk for peri‐implant osteolysis long before the emergence of radiographic signs. Further, the high accuracy of the pre‐operative biomarker levels demonstrates the potential importance of pre‐existing, patient‐specific factors driving subsequent osteolysis. The study was published on June 5, 2018, in the Journal of Orthopaedic Research.

Related Links:
Rush University Medical Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.